XORTX Therapeutics (XRTX) Return on Capital Employed (2021 - 2024)

XORTX Therapeutics' (XRTX) quarterly Return on Capital Employed came in at 83.06% in Q3 2023, down 37.59% on a QoQ basis from 60.37% in Q2 2023.

XORTX Therapeutics (XRTX) Return on Capital Employed (2021 - 2024) Analysis & Trends

XORTX Therapeutics (XRTX) has 3 years of Return on Capital Employed data on file, last reported at 83.06% in Q3 2023.

Quarterly Return on Capital Employed changed N/A year-over-year to 83.06% in Q3 2023, while the trailing twelve-month figure through Sep 2023 was 83.06% (changed N/A YoY) and the FY2023 annual result came in at 22.08%, up 5415.0% from the prior year.
Return on Capital Employed declined to 83.06% in Q3 2023, from 60.37% in the prior quarter.
In the past five years, Return on Capital Employed ranged from a high of 11.78% in Q4 2021 to a low of 83.06% in Q3 2023.
A 3-year average of 53.82% and a median of 60.22% in 2023 frame the typical range for Return on Capital Employed.
The widest YoY moves for Return on Capital Employed: up 4828 bps in 2022, down 4828 bps in 2022.
Tracing XRTX's Return on Capital Employed over 3 years: stood at 11.78% in 2021, then plunged by 410 bps to 60.06% in 2022, then plunged by 38 bps to 83.06% in 2023.
The last three Return on Capital Employed figures came in at 83.06% (Q3 2023), 60.37% (Q2 2023), and 60.06% (Q4 2022), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Vertex Pharmaceuticals	139.94 Bn	132.09 Bn	2.84 Bn	20.76%
2	Regeneron Pharmaceuticals	86.59 Bn	78.60 Bn	3.93 Bn	10.74%
3	Argenx Se	65.67 Bn	60.49 Bn	1.37 Bn	-
4	Moderna	57.81 Bn	52.67 Bn	52.00 Mn	-38.20%
5	BeOne Medicines	42.25 Bn	37.15 Bn	1.53 Bn	13.68%
6	Alnylam Pharmaceuticals	31.76 Bn	28.45 Bn	992.69 Mn	26.09%
7	BioNTech SE	28.41 Bn	10.02 Bn	668.28 Mn	-6.85%
8	Insmed	27.58 Bn	26.42 Bn	358.27 Mn	-50.93%
9	Royalty Pharma	27.24 Bn	26.41 Bn	-	7.88%
10	XORTX Therapeutics	2.84 Mn	2.84 Mn	-	-

Download Data